How FDA approval takes Oncosil Medical Ltd closer to the Holy Grail

Oncosil Medical Ltd (ASX:OSL) shares are soaring today after it received FDA approval for its OncoSil pancreatic cancer treatment study. Is it too soon to invest?

a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The share price of Oncosil Medical Ltd (ASX: OSL) rocketed higher by over 20% today after the late-stage medical devices company announced that it has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA).

After an intensive eight month process of submissions and interactions with the FDA, it now means the company can initiate a pivotal clinical investigation for OncoSil for the treatment of eligible subjects with pancreatic cancer.

The OncoPac-1 global study is intended to include up to 30 centres in the United States and other international markets including the United Kingdom, Europe, and of course Australia. A total of 300 subjects will be recruited with locally advanced unresectable adenocarcinoma of the pancreas.

The release went on to explain that the study is expected to enrol the first subject in early 2017 and recruitment is anticipated to take approximately two years, with each patient to be followed until disease progression. Subjects will then be followed for overall survival until death, or until the last enrolled study patient has completed 52-weeks of overall survival follow-up.

Whilst this is a very promising bit of news for Oncosil Medical and its shareholders, it will still be a long time before we see any notable results and financial gain from the study. I believe the company has just enough cash on hand to see it through the study, but it will be a tight affair.

At this point in time it is a little too speculative for my liking, but I would definitely suggest adding it to your watch list in order to stay up to date with its progress. In the meantime I would recommend taking a closer look at CSL Limited (ASX: CSL), Pro Medicus Limited (ASX: PME), and Sirtex Medical Limited (ASX: SRX) as alternative investments.

Motley Fool contributor James Mickleboro has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »